DOCSLIB.ORG

To View the Lab Test Catalog

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
To View the Lab Test Catalog Test Catalog 09/19/2021 OU MEDICAL CENTER Laboratory offers a listing of the clinical tests, as well as information regarding turn-around times, specimen requirements, reference ranges, patient requirements, etc in this test catalog. Microbiology testing follows the clinical listing. The test catalog is fully searchable via Adobe Reader's search functions (Adobe 5 or higher required). To search online for a test, click on the Search icon in the Adobe Reader Toolbar area....it looks like a pair of binoculars. Type the word or portion of the word that you would like to find and press the Enter key. Contact the Laboratory at (405)271-3260 to obtain further information. [11BPGD2U] Ur 11 beta-Prostaglandin F2 alpha SPECIMEN REQUIRED: Refrigerated or frozen urine (24-hour (collection) TUBE OR CONTAINER: Plastic urine container SPECIAL HANDLING: Collect 24-hour urine in "D" container (6N HCl) SPECIMEN VOLUME: 5 mL MINIMUM VOLUME: 1 mL TEST AVAILABILITY: Daily TURNAROUND TIME: 3-7 days REFERENCE RANGE: < 1382 pg/mg creatinine METHODOLOGY: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) AACT: Enzymatic Colorimetric Assay CPT: 84150 [17HCS] UR 17 HYDROXYCORTICOSTEROIDS SPECIMEN REQUIRED: Frozen urine (24 hour collection) TUBE OR CONTAINER: Plastic urine container acid) or "P" container (no preservative). All drugs should be withheld for 72 hours prior to collection, if possible Sample pH must be between 5.0-7.0 SPECIMEN VOLUME: 12 mL MINIMUM VOLUME: 6 mL TEST AVAILABILITY: Daily TURNAROUND TIME: 4-8 days REFERENCE RANGE: 2.0-6.5 mg/g creatinine 4.0-14.0 mg/day OTHER NAMES: 17-OHCS, Urine; Porter-Silber Chromogens, Urine METHODOLOGY: Quantitative Colorimetry CLINICAL USE: Adrenal function test useful in evaluation of glucocorticoid production; increased in ectopic ACTH syndrome, Cushing syndrome and stress; decreased in Addison's disease, adrenogenital syndrome, pituitary insufficiency CPT: 83941 [17HYD] 17-Hydroxyprogesterone SPECIMEN REQUIRED: Refrigerated serum or plasma TUBE OR CONTAINER: Red, Gold or Lavender (EDTA) SPECIMEN VOLUME: 1 mL MINIMUM VOLUME: 0.5 mL (this volume does not allow for repeat testing) PEDIATRIC TEST INFO: Order PED17HYD for pediatric testing to be performed by Esoterix TEST AVAILABILITY: Daily TURNAROUND TIME: 2-3 days REFERENCE RANGE: Age-specific METHODOLOGY: Liquid chromatography/tandem mass spectrometry (LC/MS-MS) CLINICAL USE: Markedly elevated in patients with congenital adrenal hyperplasia (adrenogenital syndrome) due to 21-hydroxylase deficiency; evaluate hirsutism and/or infertility; assess certain adrenal or ovarian tumors with endocrine activity CPT: 83498 [17KET24] UR 17 KETOSTEROIDS TOTAL SPECIMEN REQUIRED: Refrigerated or frozen urine (24 hour collection), random sample is acceptable TUBE OR CONTAINER: Plastic urine container SPECIAL HANDLING: Collect urine in "P" or "D" container (30mLs 6N HCL) Refrigerate during collection; Final pH must be 2-4 SPECIMEN VOLUME: 5 mL MINIMUM VOLUME: 3 mL TEST AVAILABILITY: Daily TURNAROUND TIME: 3-7 days REFERENCE RANGE: 0-11 months: 0.0-1.0 mg/d 1-5 years: 1.0-2.0 mg/d 6-10 years: 1.0-4.4 mg/d (male) 1.4-3.9 mg/d (female) 11-12 years: 1.3-8.5 mg/d (male) 3.5-9.5 mg/d (female) 13-16 years: 3.4-9.8 mg/d (male) 4.5-17.1 mg/d (female) 17-50 years: 5.3-17.6 mg/d (male) 4.4-14.2 mg/d (female) 51 years and older: 4.1-12.1 mg/d (male) 3.2-10.6 mg/d (female) METHODOLOGY: Quantitative Spectrophotometry (Zimmerman) CLINICAL USE: Assess adrenal androgens CPT: 82570; 83586 [17OHPREG] 17-Hydroxy-Pregnenolone SPECIMEN REQUIRED: Frozen serum or plasma TUBE OR CONTAINER: Red, Gold or Lavender (EDTA) SPECIMEN VOLUME: 1 mL SPECIMEN VOLUME: 1 mL MINIMUM VOLUME: 0.3 mL (this volume does not allow for repeat testing) PEDIATRIC TEST INFO: Order PED17OHP for pediatric testing to be performed by Esoterix TEST AVAILABILITY: Daily REFERENCE RANGE: Male: 10-100 ng/dL Female: 10-250 ng/dL METHODOLOGY: Radioimmunoassay (RIA) CPT: 84143 [1P19QFISH] 1p & 19q IN SITU HYBRIDIZATION SPECIMEN REQUIRED: Formalin-fixed, paraffin-embedded (FFPE) tissue biopsy at room temperature or Unstained slides and H&E TUBE OR CONTAINER: Slides or blocks SPECIMEN VOLUME: 6 unstained slides and 1 H&E stained side at 10 uM or tissue block TEST AVAILABILITY: Daily METHODOLOGY: In situ hybridization CPT: 88368 x 4 [21HYDAB] 21-Hydroxylase Antibody SPECIMEN REQUIRED: Frozen serum or plasma TUBE OR CONTAINER: Red, Gold or Lavender (EDTA) SPECIAL HANDLING: Separate serum or plasma from cells within 1 hour of collection SPECIMEN VOLUME: 1 mL MINIMUM VOLUME: 0.2 mL TEST AVAILABILITY: Daily TURNAROUND TIME: 2-9 days METHODOLOGY: Radioimmunoassay Immunoprecipitation CLINICAL USE: Investigation of adrenal insufficiency; Aid in the detection of those at risk of developing autoimmune adrenal failure in the future CPT: 83519 [23DINOR] 11 beta-Prostaglandin F2 alpha [5FLUOR] 5-Fluorocytosine Level SPECIMEN REQUIRED: Refrigerated serum or plasma TUBE OR CONTAINER: Red (no gel) or Lavender (EDTA) SPECIMEN VOLUME: 1 mL MINIMUM VOLUME: 0.3 mL TEST AVAILABILITY: Daily TURNAROUND TIME: 7-10 days OTHER NAMES: 5FC; 5-Fluorouracil; 5-Fluorocytosine Ancobon Flucytosine METHODOLOGY: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS) CPT: 80299 [5HIAA] UR HYDROXYINDOLEACETIC ACID QT SPECIMEN REQUIRED: Room temperature urine (24-hour collection) TUBE OR CONTAINER: Plastic urine container SPECIAL HANDLING: 24 hour urine collected in "P" container (no preservative); boric acid may be added as a preservative for other tests without harm to 5-HIAA however, pH can not be less than 2 SPECIMEN VOLUME: 30 mL MINIMUM VOLUME: 1 mL TEST AVAILABILITY: Daily TURNAROUND TIME: 2 days REFERENCE RANGE: 0.0-14.9 mg/24 hours OTHER NAMES: Serotonin Metabolite, Urine METHODOLOGY: Liquid chromatography/Tandem Mass Spectrometry (LC-MS/MS) CLINICAL USE: 5-HIAA is the major urinary metabolite of serotonin; both are produced in excess by most carcinoid tumors CPT: 83947 [5HIAARAN] HYDROXYINDOLEACETIC ACID RANDO SPECIMEN REQUIRED: Room temperature urine (random) TUBE OR CONTAINER: Plastic urine container SPECIAL HANDLING: Plastic urine container, no preservative. (Note: Boric acid may be added as a preservative for other tests without harm to 5-HIAA.) SPECIMEN VOLUME: 1 mL MINIMUM VOLUME: 0.3 mL TEST AVAILABILITY: Daily TURNAROUND TIME: 2-3 days REFERENCE RANGE: Pediatrics: 0-3 years: 0.0-16.2 mg/g creatinine 9-12 years: 0.0-8.7 mg/g creatinine 13-18 years: 0.0-5.5 mg/g creatinine > 18 years: 0.0-6.9 mg/g creatinine METHODOLOGY: Liquid chromatography/Tandem Mass Spectrometry (LC-MS/MS) CLINICAL USE: 5 -HIAA is the major urinary metabolite of serotonin; both are produced in excess by most carcinoid tumors CPT: 82570; 83947 [A1APH] ALPHA 1 ANTITRYPSIN PHENOTYPIN SPECIMEN REQUIRED: Room Temp serum; overnight fast preferred TUBE OR CONTAINER: Red or gold SPECIMEN VOLUME: 2 mL MINIMUM VOLUME: 1 mL TEST INCLUDES: Alpha-1-Antitrypsin, total; and phenotype TEST AVAILABILITY: Daily TURNAROUND TIME: 1-2 days REFERENCE RANGE: Interpretation accompanies report OTHER NAMES: A1A Phenotyping; A1AT Phenotype; AAT Phenotype; Pi Phenotype; Protease Inhibitors METHODOLOGY: Phenotype: Isoelectric Focusing (IEF) Total: Immunologic CLINICAL USE: Definitive analysis of hereditary alpha-1- antitrypsin deficiency, which is associated with chronic obstructive pulmonary disease (COPD) (panacinar emphysema), hepatic cirrhosis, and hepatoma CPT: 82103; 82104 [A1ASTL] Stool Alpha-1-Antitrypsin SPECIMEN REQUIRED: Frozen stool TUBE OR CONTAINER: Screw-cap container SPECIMEN VOLUME: 5 gram MINIMUM VOLUME: 1 gram TEST AVAILABILITY: Daily TURNAROUND TIME: 2-4 days REFERENCE RANGE: < 0.62 mg/g METHODOLOGY: Radial Immunodiffusion CPT: 82103 [A1GLY] Alpha-1-Acid Glycoprotein SPECIMEN REQUIRED: Frozen serum TUBE OR CONTAINER: Red or gold CAUSE FOR REJECTION: Gross lipemia that cannot be cleared by ultracentrifugation SPECIMEN VOLUME: 1 mL MINIMUM VOLUME: 0.5 mL TEST AVAILABILITY: Daily TURNAROUND TIME: 3-5 days REFERENCE RANGE: 18 years and older: 50-120 mg/dL METHODOLOGY: Immunologic CLINICAL USE: Decreased serum levels may be found in association with malnutrition, severe liver damage, and in women using estrogen-related oral contraceptives. Increased levels have been reported in conditions of acute and chronic inflammation, including myocardial infarction, rheumatoid arthritis, systemic lupus erythematosus, and malignancy CPT: 82985 [ACCEL] Accelerate Pheno Test [ACE] Angiotensin Converting Enzyme SPECIMEN REQUIRED: Refrigerated serum TUBE OR CONTAINER: Red or Gold icteric sample SPECIMEN VOLUME: 1 mL MINIMUM VOLUME: 0.5 mL TEST AVAILABILITY: Daily TURNAROUND TIME: 48 hours REFERENCE RANGE: 0-2 years: 18-95 units/L 3-14 years: 22-108 units/L 15 years or older: 14-82 units/L METHODOLOGY: Kinetic CLINICAL USE: High in sarcoidosis, more often when the disease is active; assessment of the response of sarcoidosis to corticosteroid therapy CPT: 82164 [ACECSF] CSF Angiotensin Converting Enzyme SPECIMEN REQUIRED: Frozen CSF TUBE OR CONTAINER: Sterile conical/capped tube SPECIMEN VOLUME: 0.5 mL MINIMUM VOLUME: 0.2 mL TEST AVAILABILITY: Daily TURNAROUND TIME: 3-7 days REFERENCE RANGE: 0.0-2.5 U/L METHODOLOGY: Spectrophotometry CLINICAL USE: May be used to support the diagnosis of sarcoidosis or neurosarcoidosis CPT: 82164 [ACET] Acetaminophen Level SPECIMEN REQUIRED: Refrigerated plasma or serum TUBE OR CONTAINER: Light Green (heparin) or Gold SPECIAL HANDLING: When evaluating for possible toxicity, a 4 to 6 post-ingestion sample should be drawn Collect a second sample
Load more

Recommended publications
  • Targeting the LKB1 Tumor Suppressor
    Send Orders for Reprints to [email protected] 32 Current Drug Targets, 2014, 15, 32-52 Targeting the LKB1 Tumor Suppressor Rui-Xun Zhao and Zhi-Xiang Xu* Division of Hematology and Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA Abstract: LKB1 (also known as serine-threonine kinase 11, STK11) is a tumor suppressor, which is mutated or deleted in Peutz-Jeghers syndrome (PJS) and in a variety of cancers. Physiologically, LKB1 possesses multiple cellular functions in the regulation of cell bioenergetics metabolism, cell cycle arrest, embryo development, cell polarity, and apoptosis. New studies demonstrated that LKB1 may also play a role in the maintenance of function and dynamics of hematopoietic stem cells. Over the past years, personalized therapy targeting specific genetic aberrations has attracted intense interests. Within this review, several agents with potential activity against aberrant LKB1 signaling have been discussed. Potential strate- gies and challenges in targeting LKB1 inactivation are also considered. Keywords: LKB1 (serine-threonine kinase 11, STK11), AMP-activated protein kinase (AMPK), tumor suppression, mutations, targeting therapeutics. INTRODUCTION THE BIOLOGICAL FUNCTIONS OF LKB1 The LKB1 gene, also known as serine-threonine kinase Cell Metabolism 11 (STK11), was first identified by Jun-ichi Nezu of Chugai About a decade ago, studies from three different groups Pharmaceuticals in 1996 in a screen aimed at identifying new established that LKB1 is the long-sought kinase that phos- kinases [1]. The human LKB1 gene has been mapped to phorylates AMPK [9-11]. AMPK is a heterotrimeric enzyme chromosome 19p13.3. The gene spans 23 kb and is com- complex consisting of a catalytic subunit and regulatory posed of nine coding exons and a noncoding exon [2].
    [Show full text]
  • Genetics of Interleukin 1 Receptor-Like 1 in Immune and Inflammatory Diseases
    Current Genomics, 2010, 11, 591-606 591 Genetics of Interleukin 1 Receptor-Like 1 in Immune and Inflammatory Diseases Loubna Akhabir and Andrew Sandford* Department of Medicine, University of British Columbia, UBC James Hogg Research Centre, Providence Heart + Lung Institute, Room 166, St. Paul's Hospital, 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada Abstract: Interleukin 1 receptor-like 1 (IL1RL1) is gaining in recognition due to its involvement in immune/inflamma- tory disorders. Well-designed animal studies have shown its critical role in experimental allergic inflammation and human in vitro studies have consistently demonstrated its up-regulation in several conditions such as asthma and rheumatoid ar- thritis. The ligand for IL1RL1 is IL33 which emerged as playing an important role in initiating eosinophilic inflammation and activating other immune cells resulting in an allergic phenotype. An IL1RL1 single nucleotide polymorphism (SNP) was among the most significant results of a genome-wide scan inves- tigating eosinophil counts; in the same study, this SNP associated with asthma in 10 populations. The IL1RL1 gene resides in a region of high linkage disequilibrium containing interleukin 1 receptor genes as well as in- terleukin 18 receptor and accessory genes. This poses a challenge to researchers interested in deciphering genetic associa- tion signals in the region as all of the genes represent interesting candidates for asthma and allergic disease. The IL1RL1 gene and its resulting soluble and receptor proteins have emerged as key regulators of the inflammatory proc- ess implicated in a large variety of human pathologies We review the function and expression of the IL1RL1 gene.
    [Show full text]
  • Identification of Novel Pathways That Promote Anoikis Through Genome-Wide Screens
    University of Massachusetts Medical School eScholarship@UMMS GSBS Dissertations and Theses Graduate School of Biomedical Sciences 2016-10-14 Identification of Novel Pathways that Promote Anoikis through Genome-wide Screens Victoria E. Pedanou University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss Part of the Biology Commons, and the Cancer Biology Commons Repository Citation Pedanou VE. (2016). Identification of Novel Pathways that Promote Anoikis through Genome-wide Screens. GSBS Dissertations and Theses. https://doi.org/10.13028/M27G6D. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/889 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. i TITLE PAGE IDENTIFICATION OF NOVEL PATHWAYS THAT PROMOTE ANOIKIS THROUGH GENOME-WIDE SCREENS A Dissertation Presented By VICTORIA ELIZABETH PEDANOU Submitted to the Faculty of the University of Massachusetts Graduate School of Biomedical Sciences, Worcester in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY OCTOBER 14TH, 2016 CANCER BIOLOGY ii SIGNATURE PAGE IDENTIFICATION OF NOVEL PATHWAYS THAT PROMOTE ANOIKIS THROUGH GENOME-WIDE SCREENS A Dissertation Presented By VICTORIA ELIZABETH PEDANOU This work was undertaken in the Graduate School of Biomedical Sciences Cancer Biology The signature of the Thesis Advisor signifies validation of Dissertation content ___________________________ Michael R. Green, Thesis Advisor The signatures of the Dissertation Defense Committee signify completion and approval as to style and content of the Dissertation __________________________________ Eric H.
    [Show full text]
  • Human Plasma and Recombinant Hemopexins: Heme Binding Revisited
    International Journal of Molecular Sciences Article Human Plasma and Recombinant Hemopexins: Heme Binding Revisited Elena Karnaukhova 1,*, Catherine Owczarek 2, Peter Schmidt 2, Dominik J. Schaer 3 and Paul W. Buehler 4,5,* 1 Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA 2 CSL Limited, Bio21 Institute, Parkville, Victoria 3010, Australia; [email protected] (C.O.); [email protected] (P.S.) 3 Division of Internal Medicine, University Hospital of Zurich, 8091 Zurich, Switzerland; [email protected] 4 Department of Pathology, The University of Maryland School of Medicine, Baltimore, MD 21201, USA 5 The Center for Blood Oxygen Transport and Hemostasis, Department of Pediatrics, The University of Maryland School of Medicine, Baltimore, MD 21201, USA * Correspondence: [email protected] (E.K.); [email protected] (P.W.B.) Abstract: Plasma hemopexin (HPX) is the key antioxidant protein of the endogenous clearance pathway that limits the deleterious effects of heme released from hemoglobin and myoglobin (the term “heme” is used in this article to denote both the ferrous and ferric forms). During intra-vascular hemolysis, heme partitioning to protein and lipid increases as the plasma concentration of HPX declines. Therefore, the development of HPX as a replacement therapy during high heme stress could be a relevant intervention for hemolytic disorders. A logical approach to enhance HPX yield involves recombinant production strategies from human cell lines. The present study focuses on a biophysical assessment of heme binding to recombinant human HPX (rhHPX) produced in the Expi293FTM (HEK293) cell system.
    [Show full text]
  • Overexpression and Selective Anticancer Efficacy of ENO3 in STK11 Mutant Lung Cancers
    Molecules and Cells Overexpression and Selective Anticancer Efficacy of ENO3 in STK11 Mutant Lung Cancers Choa Park1,3, Yejin Lee1,3, Soyeon Je1,3, Shengzhi Chang1, Nayoung Kim1, Euna Jeong2, and Sukjoon 1,2, Yoon * 1Department of Biological Sciences, Sookmyung Women’s University, Seoul 04310, Korea, 2Research Institute of Women’s Health, Sookmyung Women’s University, Seoul 04310, Korea, 3These authors contributed equally to this work. *Correspondence: [email protected] https://doi.org/10.14348/molcells.2019.0099 www.molcells.org Oncogenic gain-of-function mutations are clinical biomarkers lung cancer, constituting ~80% to 90% of all lung can- for most targeted therapies, as well as represent direct targets cers (Novello et al., 2016; Planchard et al., 2018). NSCLC for drug treatment. Although loss-of-function mutations is classified into three types: lung adenocarcinoma (LUAD), involving the tumor suppressor gene, STK11 (LKB1) are squamous cell carcinoma, and large cell carcinoma. LUAD important in lung cancer progression, STK11 is not the direct accounts for approximately 30% of lung cancers (Gill et al., target for anticancer agents. We attempted to identify cancer 2011). Serine/threonine kinase 11 (STK11), also known as liv- transcriptome signatures associated with STK11 loss-of- er kinase B1 (LKB1), is a major tumor suppressor gene in lung function mutations. Several new sensitive and specific gene cancers. Particularly, STK11 is the most inactivated tumor expression markers (ENO3, TTC39C, LGALS3, and MAML2) suppressor gene in NSCLC (Carretero et al., 2004; Chen et were identified using two orthogonal measures, i.e., fold al., 2016; Facchinetti et al., 2017). Although STK11 inactiva- change and odds ratio analyses of transcriptome data from tion (i.e., loss-of-function mutation) occurs in ~30% of LUAD cell lines and tissue samples.
    [Show full text]
  • New York Chapter American College of Physicians Annual
    New York Chapter American College of Physicians Annual Scientific Meeting Poster Presentations Saturday, October 12, 2019 Westchester Hilton Hotel 699 Westchester Avenue Rye Brook, NY New York Chapter American College of Physicians Annual Scientific Meeting Medical Student Clinical Vignette 1 Medical Student Clinical Vignette Adina Amin Medical Student Jessy Epstein, Miguel Lacayo, Emmanuel Morakinyo Touro College of Osteopathic Medicine A Series of Unfortunate Events - A Rare Presentation of Thoracic Outlet Syndrome Venous thoracic outlet syndrome, formerly known as Paget-Schroetter Syndrome, is a condition characterized by spontaneous deep vein thrombosis of the upper extremity. It is a very rare syndrome resulting from anatomical abnormalities of the thoracic outlet, causing thrombosis of the deep veins draining the upper extremity. This disease is also called “effort thrombosis― because of increased association with vigorous and repetitive upper extremity activities. Symptoms include severe upper extremity pain and swelling after strenuous activity. A 31-year-old female with a history of vascular thoracic outlet syndrome, two prior thrombectomies, and right first rib resection presented with symptoms of loss of blood sensation, dull pain in the area, and sharp pain when coughing/sneezing. When the patient had her first blood clot, physical exam was notable for swelling, venous distension, and skin discoloration. The patient had her first thrombectomy in her right upper extremity a couple weeks after the first clot was discovered. Thrombolysis with TPA was initiated, and percutaneous mechanical thrombectomy with angioplasty of the axillary and subclavian veins was performed. Almost immediately after the thrombectomy, the patient had a rethrombosis which was confirmed by ultrasound.
    [Show full text]
  • Interleukin-18 As a Therapeutic Target in Acute Myocardial Infarction and Heart Failure
    Interleukin-18 as a Therapeutic Target in Acute Myocardial Infarction and Heart Failure Laura C O’Brien,1 Eleonora Mezzaroma,2,3,4 Benjamin W Van Tassell,2,3,4 Carlo Marchetti,2,3 Salvatore Carbone,2,3 Antonio Abbate,1,2,3 and Stefano Toldo2,3 1Department of Physiology and Biophysics, 2Victoria Johnson Research Laboratories, and 3Virginia Commonwealth University Pauley Heart Center, School of Medicine, and 4Pharmacotherapy and Outcome Sciences, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, United States of America Interleukin 18 (IL-18) is a proinflammatory cytokine in the IL-1 family that has been implicated in a number of disease states. In animal models of acute myocardial infarction (AMI), pressure overload, and LPS-induced dysfunction, IL-18 regulates cardiomy- ocyte hypertrophy and induces cardiac contractile dysfunction and extracellular matrix remodeling. In patients, high IL-18 levels correlate with increased risk of developing cardiovascular disease (CVD) and with a worse prognosis in patients with established CVD. Two strategies have been used to counter the effects of IL-18:IL-18 binding protein (IL-18BP), a naturally occurring protein, and a neutralizing IL-18 antibody. Recombinant human IL-18BP (r-hIL-18BP) has been investigated in animal studies and in phase I/II clinical trials for psoriasis and rheumatoid arthritis. A phase II clinical trial using a humanized monoclonal IL-18 antibody for type 2 diabetes is ongoing. Here we review the literature regarding the role of IL-18 in AMI and heart failure and the evidence and challenges of using IL-18BP and blocking IL-18 antibodies as a therapeutic strategy in patients with heart disease.
    [Show full text]
  • Role of Cornification and Triglyceride Synthesis Genes
    Gillespie et al. BMC Genomics 2013, 14:169 http://www.biomedcentral.com/1471-2164/14/169 RESEARCH ARTICLE Open Access Transcriptome analysis of pigeon milk production – role of cornification and triglyceride synthesis genes Meagan J Gillespie1,2*, Tamsyn M Crowley1,3, Volker R Haring1, Susanne L Wilson1, Jennifer A Harper1, Jean S Payne1, Diane Green1, Paul Monaghan1, John A Donald2, Kevin R Nicholas3 and Robert J Moore1 Abstract Background: The pigeon crop is specially adapted to produce milk that is fed to newly hatched young. The process of pigeon milk production begins when the germinal cell layer of the crop rapidly proliferates in response to prolactin, which results in a mass of epithelial cells that are sloughed from the crop and regurgitated to the young. We proposed that the evolution of pigeon milk built upon the ability of avian keratinocytes to accumulate intracellular neutral lipids during the cornification of the epidermis. However, this cornification process in the pigeon crop has not been characterised. Results: We identified the epidermal differentiation complex in the draft pigeon genome scaffold and found that, like the chicken, it contained beta-keratin genes. These beta-keratin genes can be classified, based on sequence similarity, into several clusters including feather, scale and claw keratins. The cornified cells of the pigeon crop express several cornification-associated genes including cornulin, S100-A9 and A16-like, transglutaminase 6-like and the pigeon ‘lactating’ crop-specific annexin cp35. Beta-keratins play an important role in ‘lactating’ crop, with several claw and scale keratins up-regulated. Additionally, transglutaminase 5 and differential splice variants of transglutaminase 4 are up-regulated along with S100-A10.
    [Show full text]
  • Leigh Syndrome: One Disorder, More Than 75 Monogenic Causes
    Title: Leigh Syndrome: One disorder, more than 75 monogenic causes Running head: Leigh Syndrome: One disorder, many genes Author list: Nicole J. Lake, MSc,1,2 Alison G. Compton, PhD,1,2 Shamima Rahman, MD, PhD,3 and David R. Thorburn, PhD1,2,4 Affiliations: From the 1Murdoch Childrens Research Institute, Royal Children's Hospital, Melbourne, Victoria, Australia; 2Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia; 3Mitochondrial Research Group, Genetics and Genomic Medicine, Institute of Child Health, University College London and Metabolic Unit, Great Ormond Street Hospital, London, United Kingdom; 4Victorian Clinical Genetic Services, Royal Children's Hospital, Melbourne, Victoria, Australia. Corresponding author: Prof. David Thorburn Email [email protected] Telephone +61 3 8341 6235 Fax +61 3 8341 6212 Address Murdoch Childrens Research Institute, The Royal Children’s Hospital, 50 Flemington Rd, Parkville, Victoria, 3052, Australia Number of characters in the title and running head: 51 and 35, respectively Number of words in the abstract (107), and the body of manuscript not including abstract (4877) Number of figures (3), colour figures (1/3), and tables (3) 1 Abstract Leigh syndrome is the most common pediatric presentation of mitochondrial disease. This neurodegenerative disorder is genetically heterogeneous, and to date pathogenic mutations in more than 75 genes have been identified, encoded by two genomes (mitochondrial and nuclear). More than a third of these disease genes have been characterized in the last 5 years alone, reflecting the significant advances made in understanding its etiological basis. We review the diverse biochemical and genetic etiology of Leigh syndrome and associated clinical, neuroradiological and metabolic features that can provide clues for diagnosis.
    [Show full text]
  • MASSHEALTH TRANSMITTAL LETTER LAB-22 July 2002 TO
    Commonwealth of Massachusetts Executive Office of Health and Human Services Division of Medical Assistance 600 Washington Street Boston, MA 02111 www.mass.gov/dma MASSHEALTH TRANSMITTAL LETTER LAB-22 July 2002 TO: Independent Clinical Laboratories Participating in MassHealth FROM: Wendy E. Warring, Commissioner RE: Independent Clinical Laboratory Manual (Laboratory HCPCS) The federal government has revised the HCFA Common Procedure Coding System (HCPCS) for MassHealth billing. This letter transmits changes for your provider manual that contain the new and revised codes. The revised Subchapter 6 is effective for dates of service on or after April 30, 2002. The codes introduced under the 2002 HCPCS code book are effective for dates of service on or after April 30, 2002. We will accept either the new or the old codes for dates of service through July 28, 2002. For dates of service on or after July 29, 2002, you must use the new codes to receive payment. If you wish to obtain a fee schedule, you may purchase Division of Health Care Finance and Policy regulations from either the Massachusetts State Bookstore or from the Division of Health Care Finance and Policy (see addresses and telephone numbers below). You must contact them first to find out the price of the publication. The Division of Health Care Finance and Policy also has the regulations available on disk. The regulation title for laboratory is 114.3 CMR 20.00: Laboratory. Massachusetts State Bookstore Division of Health Care Finance and Policy State House, Room 116 Two Boylston Street
    [Show full text]
  • Anti-Inflammatory Role of Curcumin in LPS Treated A549 Cells at Global Proteome Level and on Mycobacterial Infection
    Anti-inflammatory Role of Curcumin in LPS Treated A549 cells at Global Proteome level and on Mycobacterial infection. Suchita Singh1,+, Rakesh Arya2,3,+, Rhishikesh R Bargaje1, Mrinal Kumar Das2,4, Subia Akram2, Hossain Md. Faruquee2,5, Rajendra Kumar Behera3, Ranjan Kumar Nanda2,*, Anurag Agrawal1 1Center of Excellence for Translational Research in Asthma and Lung Disease, CSIR- Institute of Genomics and Integrative Biology, New Delhi, 110025, India. 2Translational Health Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, 110067, India. 3School of Life Sciences, Sambalpur University, Jyoti Vihar, Sambalpur, Orissa, 768019, India. 4Department of Respiratory Sciences, #211, Maurice Shock Building, University of Leicester, LE1 9HN 5Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia- 7003, Bangladesh. +Contributed equally for this work. S-1 70 G1 S 60 G2/M 50 40 30 % of cells 20 10 0 CURI LPSI LPSCUR Figure S1: Effect of curcumin and/or LPS treatment on A549 cell viability A549 cells were treated with curcumin (10 µM) and/or LPS or 1 µg/ml for the indicated times and after fixation were stained with propidium iodide and Annexin V-FITC. The DNA contents were determined by flow cytometry to calculate percentage of cells present in each phase of the cell cycle (G1, S and G2/M) using Flowing analysis software. S-2 Figure S2: Total proteins identified in all the three experiments and their distribution betwee curcumin and/or LPS treated conditions. The proteins showing differential expressions (log2 fold change≥2) in these experiments were presented in the venn diagram and certain number of proteins are common in all three experiments.
    [Show full text]
  • Test Directory
    800.541.7891 509.755.8600 Test Directory Fax 509.921.7107 Billing Code Test Code [sunquest] (1,3)-BETA-D-GLUCAN (FUNGITELL) 13BGA 13BGA Synonyms Fungitell; Glucan Container Type Red top tube (plain) Store and Transport Refrigerated Specimen Type Serum Preferred Volume 2 mL Minimum Volume 0.5 mL Specimen Processing Separate serum from cells within 2 hours of collection and transfer to a standard PAML aliquot tube Room Temp Unacceptable Refrigerated 2 weeks Frozen (-20°C) 2 weeks Unacceptable Condition Hemolyzed, lipemic and icteric samples Reference Laboratory ARUP Reference Lab Test Code 2002434 CPT Codes 87449 Test Schedule Mon-Fri Turnaround Time 2-4 days Method Semi-Quantitative Colorimetry Test Includes (1,3-beta-D-glucan, pg/mL; (1,3-beta D-glucan Interpretation. Notes Reference ranges for pediatric patients (less than 18 years old) have not been established. Assay ranges were validated in adult subjects. Supply Item Number 1372 Billing Code Test Code [sunquest] 1, 5 ANHYDROGLUCITOL (GLYCOMARK) GLYMAR GLYMAR Synonyms Anhydroglucitol, 1,5 AD; GlycoMark® Container Type Serum separator tube (gold, brick, SST, or corvac) Store and Transport Refrigerated Specimen Type Serum Preferred Volume 1 mL Minimum Volume 0.2 mL Specimen Processing Allow serum specimen to clot completely at room temperature. Separate serum or plasma from cells and transfer to a standard PAML aliquot tube Room Temp 1 week Refrigerated 1 week Frozen (-20°C) 1 month Alternate Specimens Lavender (EDTA) Reference Laboratory ARUP Reference Lab Test Code 0081335 CPT Codes 84378 Test Schedule Mon-Fri Turnaround Time 2-4 days Method Quantitative Enzymatic Test Includes GlycoMark, ug/mL.
    [Show full text]